A randomized double-blind multicenter phase 3 study to evaluate the efficacy and safety of Pasireotide LAR in patients with Cushing's disease
ID Number 13-1374Principal Investigator(s)
Eliza B Geer
Department(s) or Division(s)
Endocrinology, Diabetes and Bone Disease
The purpose of this study is to find out if the long acting formulation of Pasireotide LAR (long acting release) is safe and has beneficial effects in people who have hypercortisolism (excess of cortisol) caused by ACTH-dependent Cushing's disease.
Recruiting Patients: Yes